ID
45947
Beskrivning
Principal Investigator: Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA MeSH: Carcinoma,Carcinoma, Non-Small-Cell Lung https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000855 The purpose of the study was to compare gene expression profiles from a cohort of crizotinib-resistant ALK-rearranged lung tumors and a cohort of treatment-naive ALK-rearranged lung tumors. Expression profiles were generated by RNA-seq. In parallel, gene expression profiles were obtained from ALK-rearranged lung cancer cell lines in the presence or absence of the ALK inhibitor TAE684. Gene expression profiles were also obtained from ALK-rearranged cells ectopically expressing genes associated with ALK inhibitor resistance that were identified from a functional genetic study.
Länk
Nyckelord
Versioner (2)
- 2024-03-15 2024-03-15 - Dr. Christian Niklas
- 2024-03-16 2024-03-16 - Madita Rudolph
Rättsinnehavare
Levi A. Garraway, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts and Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA
Uppladdad den
15 mars 2024
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
dbGaP phs000855 Resistance studies in Lung Cancer
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID and sext of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID, sample ID, and sample use variable obtained from participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Subject ID and sext of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
- Sample ID, sample type [tumor], and analyte type of participants with lung cancer and involved in the "Resistance studies in Lung Cancer" project.
C0680251 (UMLS CUI [1,2])
C0750484 (UMLS CUI [1,2])
C0599161 (UMLS CUI [1,3])
C0200345 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0087111 (UMLS CUI [2,3])
C0200345 (UMLS CUI [3,1])
C0231290 (UMLS CUI [3,2])
C2974289 (UMLS CUI [3,3])
C1514892 (UMLS CUI [3,4])